Please provide your email address to receive an email when new articles are posted on . Women with HIV have increased levels of stress, leading to problems with cognitive function. Low-dose ...

The MarketWatch News Department was not involved in the creation of this content. PARAMUS, N.J., March 9, 2026 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma, New Jersey, USA; President, Yukiteru Sugiyama ...

BSides Maine, the first hacker conference in Maine debuts May 30, 2026 in Portland with keynote by Jayson E. Street. Tickets are just $25 and include lunch. PORTLAND ...

The Scientific Laboratory Show & Conference 2026, a trade show like no other brought to you by Scientific Laboratory Supplies (SLS), the UK’s largest independent supplier to the laboratory sector, ...

Apitegromab improved motor function in SMA patients in a Phase 3 trial analysis, with stronger benefits seen in those treated earlier.

Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations ...

BOULDER, Colo., March 10, 2026 /PRNewswire/ — Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today presented at the 2026 MDA Clinical and Scientific ...

Post hoc analyses of two Phase 2 trials examine the potential benefits of solengepras, a once-daily, oral, non-dopaminergic GPR6 inhibitor, across Parkinson’s disease populationsPhase 2 adjunctive ...

Tampa General Hospital, a 1,040-bed, not-for-profit, academic medical center, is one of the largest hospitals in America and delivers world-class care ...

The Most Powerful Women 2026, presented by Grisu Media Arts and YOUx Talks e-Magazine, celebrates inspiring women whose journeys reflect resilience, purpose, and a commitment to creating meaningful ...

Svante Technologies Inc. ("Svante") announced today that its bioenergy with carbon capture and storage (BECCS) project at a paper mill in the Southeast U.S. has progressed to the feasibility study ...

RAP-219's lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026RA ...